跳至主要内容
临床试验/NCT02847312
NCT02847312Unknown不适用

Chronic Cardiovascular and Gut-bacteria Effects of Phenolic Rich Oats in Adults With Above Average Blood Pressure

University of Reading2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2016年7月最近更新:
适应症

试验速览

阶段
不适用
入组人数
30
试验地点
2
主要终点
Flow mediated dilatation

研究概览

简要总结

In this proposed human trial, the investigators aim to establish whether 4 weeks of daily consumption of beta-glucan matched meals providing either a high dose or a moderate dose of oat avenanthramides and phenolic acids leads to dose-dependent chronic improvements in markers of CVD risk and gut health relative to an energy matched control intervention in healthy adults with above average blood pressure.

详细描述

  • To investigate the chronic effects of daily intake of oat products on flow mediated dilatation of the brachial artery (FMD; primary endpoint), microvascular endothelial function (measured by laser Doppler iontophoresis), pulse wave analysis, gut microbiota diversity, 24h blood pressure, activity of the renin angiotensin system, markers related to cellular production of nitric oxide and reactive oxygen species, inflammatory cytokines, and further potentially emerging biochemical markers of CVD risk.
  • To establish if phenolic acids and avenanthramides from oat products exert cardiovascular and microbial effects in a dose dependent manner.
  • To measure urinary and fecal excretion of avenanthramide and phenolic acid metabolites.

To explore correlations between bacterial population changes and CVD risk markers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
25 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Above average blood pressure (i.e. systolic 120-159 mmHg and diastolic 75-99 mmHg)

排除标准

  • Abnormal biochemical, haematological results as assessed at health screening
  • Hypertension (i.e. SBP/DBP ≥160/100 mm Hg)
  • Current smoker or ex-smoker ceasing <3 months ago
  • Past or existing medical history of vascular disease, diabetes, hepatic, renal, haematological, neurological, thyroidal disease or cancer
  • Prescribed or taking lipid lowering, antihypertensive, vasoactive (e.g. Viagra), anti-inflammatory, antibiotic or antidepressant medication
  • Allergies to whole grains
  • Parallel participation in another research project
  • Having flu vaccination or antibiotics within 3 months of trial start
  • Chronic constipation, diarrhea or other chronic gastrointestinal complaint
  • On a weight reduction regime or taking food, probiotics or prebiotics supplements or laxative within 3 months of trial start
  • Performing high level of physical activity (i.e. ≥150min aerobic exercise/week)
  • Consumption of ≥21 units of alcohol/week
  • Females who are breast-feeding, may be pregnant, lactating or, if of reproductive age and not using a reliable form of contraception (including abstinence)

结局指标

主要结局

Flow mediated dilatation

时间窗: 20 weeks

Technique to assess the flexibility of teh endothelium in larger peripheral blood vessels, magnitude of increase in percentage from baseline to after 4 weeks treatment.

次要结局

  • Renin activity(22 weeks)
  • Plasma nitric oxide analysis(22 weeks)
  • Urine and plasma metabolomic footprint using NMR(22 weeks)
  • Gut microbiota changes(22 weeks)
  • NADPH oxidase activity in neutrophil blood cells(22 weeks)
  • Inflammatory markers(22 weeks)
  • Laser Doppler Iontophoresis(20 weeks)
  • Plasma microparticles(22 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jeremy Paul Edward Spencer

Professor

University of Reading

研究点 (2)

Loading locations...

相似试验